Our study highlights that R-2HG not only is an oncometabolite but also serves as a signal that regulates the tumor microenvironment in order to modulate immune cells and their cytokines, thus providing new mechanistic insights into the role of IDH mutations in glioma development. Here, IDH2 is linked to central nervous system cancer.